| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-31 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate |
2018-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c30c943f4ee420ba014f2c5164fdad3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69b573d3b37073b6a3132b1f1d675213 |
| publicationDate |
2020-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3675884-A1 |
| titleOfInvention |
Molecular bacteriotherapy to control skin enzymatic activity |
| abstract |
The invention provides a purified polypeptide that inhibits (i) the production and / or protease activity of keratinocytes, (ii) inhibits the production and / or activity of IL-6 of keratinocytes, (iii) inhibits production of phenol-soluble alpha 3 modulin from Staphylococcus aureus and / or (iv) inhibits S. aureus production and / or agr activity. The invention further relates to a topical formulation comprising the polypeptide. The invention relates to a recombinant microorganism comprising a vector or polynucleotide encoding the polypeptide. The invention further relates to a probiotic composition comprising the recombinant microorganism. The invention also relates to kits and manufactured articles comprising the polypeptide and / or the recombinant microorganism. |
| priorityDate |
2017-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |